Study Title
A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
Disease (Sub Disease)
Cytomegalovirus (CMV)
Diagnosis Stage
Previously treated
Collaborators
Takeda Development Center Americas, Inc.
Sites
Perth Children's Hospital
Sydney Children's Hospital
Queensland Children's Hospital
Age Eligibility
up to 17 Years
International registry ID's
NCT05319353